Cargando…

Three ileus cases associated with the use of dipeptidyl peptidase‐4 inhibitors in diabetic patients

Dipeptidyl peptidase (DPP)‐4 inhibitors are a new class of antidiabetic drugs that increase incretin hormone levels to enhance blood sugar level‐dependent insulinotropic effects, suppress glucagon action, and reduce bowel motility. These incretin effects are ideal for blood sugar control. However, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanasaki, Keizo, Konishi, Kazunori, Hayashi, Ranji, Shiroeda, Hisakazu, Nomura, Tomoe, Nakagawa, Atsushi, Nagai, Takako, Takeda‐Watanabe, Ai, Ito, Hiroki, Tsuda, Shin‐ichi, Kitada, Munehiro, Fujii, Mizue, Kanasaki, Megumi, Nishizawa, Makoto, Nakano, Yasuharu, Tomita, Yasuto, Ueda, Nobuhiko, Kosaka, Takeo, Koya, Daisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley-Blackwell 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020265/
https://www.ncbi.nlm.nih.gov/pubmed/24843724
http://dx.doi.org/10.1111/jdi.12095
_version_ 1782316041046589440
author Kanasaki, Keizo
Konishi, Kazunori
Hayashi, Ranji
Shiroeda, Hisakazu
Nomura, Tomoe
Nakagawa, Atsushi
Nagai, Takako
Takeda‐Watanabe, Ai
Ito, Hiroki
Tsuda, Shin‐ichi
Kitada, Munehiro
Fujii, Mizue
Kanasaki, Megumi
Nishizawa, Makoto
Nakano, Yasuharu
Tomita, Yasuto
Ueda, Nobuhiko
Kosaka, Takeo
Koya, Daisuke
author_facet Kanasaki, Keizo
Konishi, Kazunori
Hayashi, Ranji
Shiroeda, Hisakazu
Nomura, Tomoe
Nakagawa, Atsushi
Nagai, Takako
Takeda‐Watanabe, Ai
Ito, Hiroki
Tsuda, Shin‐ichi
Kitada, Munehiro
Fujii, Mizue
Kanasaki, Megumi
Nishizawa, Makoto
Nakano, Yasuharu
Tomita, Yasuto
Ueda, Nobuhiko
Kosaka, Takeo
Koya, Daisuke
author_sort Kanasaki, Keizo
collection PubMed
description Dipeptidyl peptidase (DPP)‐4 inhibitors are a new class of antidiabetic drugs that increase incretin hormone levels to enhance blood sugar level‐dependent insulinotropic effects, suppress glucagon action, and reduce bowel motility. These incretin effects are ideal for blood sugar control. However, the safety profile of DPP‐4 inhibitors is not yet established. Herein, we present three cases of ileus, considered to be closely related to the use of DPP‐4 inhibitors, in diabetic patients. Each of the three patients exhibited some risk of a deficiency in bowel movement; the onset of ileus was within 40 days after strengthened inhibition of DPP‐4. The use of a DPP‐4 inhibitor could be safe, although the cases presented herein enable us to inform the scientific community to some of the potential adverse effects of the use of DPP‐4 inhibitors in select populations.
format Online
Article
Text
id pubmed-4020265
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Wiley-Blackwell
record_format MEDLINE/PubMed
spelling pubmed-40202652014-05-19 Three ileus cases associated with the use of dipeptidyl peptidase‐4 inhibitors in diabetic patients Kanasaki, Keizo Konishi, Kazunori Hayashi, Ranji Shiroeda, Hisakazu Nomura, Tomoe Nakagawa, Atsushi Nagai, Takako Takeda‐Watanabe, Ai Ito, Hiroki Tsuda, Shin‐ichi Kitada, Munehiro Fujii, Mizue Kanasaki, Megumi Nishizawa, Makoto Nakano, Yasuharu Tomita, Yasuto Ueda, Nobuhiko Kosaka, Takeo Koya, Daisuke J Diabetes Investig Articles Dipeptidyl peptidase (DPP)‐4 inhibitors are a new class of antidiabetic drugs that increase incretin hormone levels to enhance blood sugar level‐dependent insulinotropic effects, suppress glucagon action, and reduce bowel motility. These incretin effects are ideal for blood sugar control. However, the safety profile of DPP‐4 inhibitors is not yet established. Herein, we present three cases of ileus, considered to be closely related to the use of DPP‐4 inhibitors, in diabetic patients. Each of the three patients exhibited some risk of a deficiency in bowel movement; the onset of ileus was within 40 days after strengthened inhibition of DPP‐4. The use of a DPP‐4 inhibitor could be safe, although the cases presented herein enable us to inform the scientific community to some of the potential adverse effects of the use of DPP‐4 inhibitors in select populations. Wiley-Blackwell 2013-05-08 2013-11-27 /pmc/articles/PMC4020265/ /pubmed/24843724 http://dx.doi.org/10.1111/jdi.12095 Text en Copyright © 2013 Asian Association for the Study of Diabetes and Wiley Publishing Asia Pty Ltd
spellingShingle Articles
Kanasaki, Keizo
Konishi, Kazunori
Hayashi, Ranji
Shiroeda, Hisakazu
Nomura, Tomoe
Nakagawa, Atsushi
Nagai, Takako
Takeda‐Watanabe, Ai
Ito, Hiroki
Tsuda, Shin‐ichi
Kitada, Munehiro
Fujii, Mizue
Kanasaki, Megumi
Nishizawa, Makoto
Nakano, Yasuharu
Tomita, Yasuto
Ueda, Nobuhiko
Kosaka, Takeo
Koya, Daisuke
Three ileus cases associated with the use of dipeptidyl peptidase‐4 inhibitors in diabetic patients
title Three ileus cases associated with the use of dipeptidyl peptidase‐4 inhibitors in diabetic patients
title_full Three ileus cases associated with the use of dipeptidyl peptidase‐4 inhibitors in diabetic patients
title_fullStr Three ileus cases associated with the use of dipeptidyl peptidase‐4 inhibitors in diabetic patients
title_full_unstemmed Three ileus cases associated with the use of dipeptidyl peptidase‐4 inhibitors in diabetic patients
title_short Three ileus cases associated with the use of dipeptidyl peptidase‐4 inhibitors in diabetic patients
title_sort three ileus cases associated with the use of dipeptidyl peptidase‐4 inhibitors in diabetic patients
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020265/
https://www.ncbi.nlm.nih.gov/pubmed/24843724
http://dx.doi.org/10.1111/jdi.12095
work_keys_str_mv AT kanasakikeizo threeileuscasesassociatedwiththeuseofdipeptidylpeptidase4inhibitorsindiabeticpatients
AT konishikazunori threeileuscasesassociatedwiththeuseofdipeptidylpeptidase4inhibitorsindiabeticpatients
AT hayashiranji threeileuscasesassociatedwiththeuseofdipeptidylpeptidase4inhibitorsindiabeticpatients
AT shiroedahisakazu threeileuscasesassociatedwiththeuseofdipeptidylpeptidase4inhibitorsindiabeticpatients
AT nomuratomoe threeileuscasesassociatedwiththeuseofdipeptidylpeptidase4inhibitorsindiabeticpatients
AT nakagawaatsushi threeileuscasesassociatedwiththeuseofdipeptidylpeptidase4inhibitorsindiabeticpatients
AT nagaitakako threeileuscasesassociatedwiththeuseofdipeptidylpeptidase4inhibitorsindiabeticpatients
AT takedawatanabeai threeileuscasesassociatedwiththeuseofdipeptidylpeptidase4inhibitorsindiabeticpatients
AT itohiroki threeileuscasesassociatedwiththeuseofdipeptidylpeptidase4inhibitorsindiabeticpatients
AT tsudashinichi threeileuscasesassociatedwiththeuseofdipeptidylpeptidase4inhibitorsindiabeticpatients
AT kitadamunehiro threeileuscasesassociatedwiththeuseofdipeptidylpeptidase4inhibitorsindiabeticpatients
AT fujiimizue threeileuscasesassociatedwiththeuseofdipeptidylpeptidase4inhibitorsindiabeticpatients
AT kanasakimegumi threeileuscasesassociatedwiththeuseofdipeptidylpeptidase4inhibitorsindiabeticpatients
AT nishizawamakoto threeileuscasesassociatedwiththeuseofdipeptidylpeptidase4inhibitorsindiabeticpatients
AT nakanoyasuharu threeileuscasesassociatedwiththeuseofdipeptidylpeptidase4inhibitorsindiabeticpatients
AT tomitayasuto threeileuscasesassociatedwiththeuseofdipeptidylpeptidase4inhibitorsindiabeticpatients
AT uedanobuhiko threeileuscasesassociatedwiththeuseofdipeptidylpeptidase4inhibitorsindiabeticpatients
AT kosakatakeo threeileuscasesassociatedwiththeuseofdipeptidylpeptidase4inhibitorsindiabeticpatients
AT koyadaisuke threeileuscasesassociatedwiththeuseofdipeptidylpeptidase4inhibitorsindiabeticpatients